B-Cell Non-Hodgkin Lymphoma

Details 406 Trials 65 Therapies

The most common type of non-Hodgkin lymphoma. It includes the most frequently seen morphologic variants which are: diffuse large B-cell lymphoma, follicular lymphoma, small lymphocytic lymphoma and marginal zone B-cell lymphoma. -- 2003

parent conditions

B-Cell Neoplasm

Non-Hodgkin Lymphoma

child conditions

Mature B-Cell Non-Hodgkin Lymphoma

Aggressive B-Cell Non-Hodgkin Lymphoma

synonyms

B-cell lymphoma

B-Cell Non-Hodgkin Lymphoma

Non-Hodgkin's B-Cell Lymphoma

B-Cell Non-Hodgkin's Lymphoma

B-Cell Non Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma B-Cell

Lymphomas Non-Hodgkin's B-Cell

Lymph node lymphoma B-cell (NOS)

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

281 sites for NCT04824092

ALK Fusion, +4 more biomarkers

ALK-Positive Large B-Cell Lymphoma, +7 more conditions

cyclophosphamide, +6 more drugs

chemotherapy, +3 more types

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

172 sites for NCT03959085

B-Cell Acute Lymphoblastic Leukemia, +2 more conditions

calaspargase pegol, +13 more drugs

chemotherapy, +2 more types

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

198 sites for NCT03267433

CCND1 Expression, +4 more biomarkers

Mantle Cell Lymphoma

autologous hematopoietic stem cell transplantation, +2 more drugs

cellular therapy, +2 more types

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

222 sites for NCT04529772

IRF4 Expression, +1 more biomarker

Diffuse Large B-Cell Lymphoma

acalabrutinib, +5 more drugs

chemotherapy, +3 more types

Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)